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In this study, the ﬁrst instrument on patient-relevant beneﬁt in the treatment of lymphedema and lipedema is
developed. The instrument can be used in both clinical practice and clinical studies to determine patient needs
and treatment outcomes.Objectives: Patient-relevant treatment beneﬁt is traditionally measured with health-related quality of life
(HRQoL) instruments. The Patient Beneﬁt Index (PBI) methodology allows for a more direct measurement, with
the patients rating both importance and achievement of treatment goals. Here, we developed and validated a
PBI version speciﬁc for the assessment of beneﬁt in lymphedema and lipedema treatment (PBI-L).
Methods: The development included ﬁve steps: (1) open item collection; (2) consensus of items in a
multidisciplinary expert panel; (3) application of the German PBI-L in a cross-sectional study (n ¼ 301); (4)
translation into English; (5) application of the English PBI-L in a randomized clinical trial (n ¼ 82). Subscales were
developed using factor analysis. Construct validity was analyzed by correlating PBI-L and convergent criteria such
as HRQoL and quality of care. To test for responsiveness, the association to change in HRQoL measures was
computed.
Results: Floor and ceiling effects were low. There were few missing values. Two well-interpretable subscales were
found with Cronbach’s alpha >0.8 each. Global and subscale scores correlated with convergent criteria and with
change in disease-speciﬁc HRQoL, but not with change in generic HRQoL.
Conclusions: The PBI-L is an internally consistent, valid, and responsive instrument for the assessment of patient-
relevant beneﬁt of edema treatment.
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Lymphedema and lipedema are chronic conditions that lead
to a progressive enlargement of the affected part of the
body which is, in most cases, the extremities. There is high
uncertainty regarding edema prevalence. Földi1 estimates
that there are as many as 4.5 million people with lymphe-
dema in Germany, corresponding to a prevalence of about
5.5%. Prevalence in the UK was estimated to be much lower
at 0.13% of the general population.2 Up to 42% of patients
with breast carcinoma are estimated to develop a second-
ary lymphedema.3 Estimations of lipedema prevalence
range from 0.06% to 10.00%.4responding author. C. Blome, German Center for Health Services
ch in Dermatology, Institute for Health Services Research in
tology and Nursing (IVDP), University Medical Center Hamburg-
orf (UKE), Martinistraße 52, Germany.
il address: c.blome@uke.de (C. Blome).
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//dx.doi.org/10.1016/j.ejvs.2013.10.009Edema management primarily includes manual lymph
drainage, compression therapy, skin care, and physical ex-
ercise.5 Patient-relevant beneﬁt of edema treatment is
usually measured using health-related quality of life
(HRQoL) instruments:6 patient beneﬁt is assumed if HRQoL
improves in the course of therapy.
In HRQoL questionnaires, beneﬁt is usually evaluated
indirectly by computing a preepost score difference. This
makes it susceptible for response shift effects, that is, a
biased assessment of treatment effect due to mere changes
in the patients’ response behavior.7 In particular, a so-called
recalibration response shift7 can occur with the patients
interpreting the response scale differently at two points in
time. For example, the same intensity of pain may be rated
as “severe” before therapy and as “slight” after therapy. As
a consequence, the two assessments may be based on a
different metric and may therefore not be comparable
anymore. Computing preepost scores can be misleading in
these cases.
The Patient Beneﬁt Index (PBI) methodology allows for a
more direct measurement of patient-relevant treatment
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(PNQ)dpatients rate the importance of a list of patient-
relevant treatment goals on a ﬁve-step scale from “not at
all” to “very”. In the second partdthe Patient Beneﬁt
Questionnaire (PBQ)dpatients rate to what extent the
treatment goals have been achieved on the same ﬁve-step
scale. Alternatively, they can choose “does not apply to me”
for each treatment goal in both questionnaires. Thus, the
patient directly evaluates treatment beneﬁt instead of rat-
ing her/his current HRQoL before and after treatment. A PBI
weighted global score ranging from 0 (no beneﬁt) to 4
(maximum beneﬁt) is computed for each patient. The
weighting algorithm8 ensures that the achievement of
important treatment goals will have higher impact on
the global score than the achievement of less important
goals. Disease-speciﬁc PBI versions have been developed
and validated for a range of different indications,
including allergic rhinitis,9 chronic pruritus,10 and chronic
wounds.11
The aim of this study was to develop and validate a PBI
version speciﬁc for the assessment of patient-relevant
beneﬁt in lymphedema and lipedema treatment (“PBI-L”).
PATIENTS AND METHODS
The PBI-L was developed and validated following the
German guidance on assessing patient reported-outcomes
in dermatology12 and international standards13,14 in a ﬁve-
step procedure: (1) open item collection; (2) expert panel
and development of the German PBI-L; (3) application of
the German PBI-L in a cross-sectional study; (4) translation
of the PBI-L into English; (5) application of the English PBI-L
in a longitudinal study.Item collection
Data on patient-relevant treatment goals were collected in
an open survey. Patients with lipedema or lymphedema
were recruited in four medical practices and two physio-
therapy practices, which were members of the “Lymph-
netz Hamburg”, a network of specialized lymph care
providers. Patients were asked to describe their treatment
goals and their impairments due to edema in their own
words.German version
The German questionnaire was developed by an expert
panel of lymphologists, dermatologists, lymph therapists,
representatives of medical stores specialized on edema
care, statisticians, experts on HRQoL assessment, and three
edema patients. The panel categorized and condensed the
patient-relevant topics collected in the open survey. The
PBI-L was created by integrating these treatment goals into
the standard PBI format.Cross-sectional study
The PBI-L was implemented in the cross-sectional
“LymphEdema Outcomes Study” (LEOS), a survey on thequality of care for edema in Hamburg, Germany. Patients
with a medically diagnosed lipedema or lymphedema of any
origin affecting the upper or lower limb and persisting for at
least 3 months were included. They were recruited via an-
nouncements in the local newspapers and by lymph care
providers.
The patients were interviewed by MD students in
advanced medical education who had been trained by
members of “Lymphnetz Hamburg”. The PBI-L was included
in a patient questionnaire along with the following
parameters.
Generic HRQoL. Generic HRQoL was measured with the EQ-
5D-3L.15 A weighted global score ranging from 0 (¼ lowest
HRQoL) to 100 (¼ highest HRQoL) was computed according
to Schulenburg et al.16 Additionally, a global assessment of
generic HRQoL in the preceding week was made by the
patients on a visual-numeric analogue scale ranging from
0 (¼ very bad) to 10 (¼ very good).
Disease-speciﬁc HRQoL. Disease-speciﬁc HRQoL was
measured with the FLQA-LK, which is a short version of the
FLQA-L (Freiburg Life Quality Assessment in Lymphe-
dema).17 The FLQA-LK global score ranges from 0 (¼ best
HRQoL) to 5 (¼ worst HRQoL).
Disease-speciﬁc health state. A global assessment on
disease-speciﬁc health state regarding the lymph condition
was given by the patients on a visualenumeric analogue
scale ranging from 0 (¼ very bad) to 10 (¼ very good).
Generic health state. General health state was assessed
with the visual analogue scale EQ VAS,15 ranging from 0 (¼
worst) to 100 (¼ best health state).
Quality of care. The quality of care from the patients’ point
of view was assessed with two items: “How do you rate the
treatment of your lymphedema so far?” (quality of care)
and “How satisﬁed are you with health care regarding your
condition?” (satisfaction with care). Patients answered on a
ﬁve-step scale ranging from 0 (¼ very bad/very unsatisﬁed)
to 4 (¼ very good/very satisﬁed).
Clinical severity. Clinical severity (edema stage) was rated
based on a clinical assessment with 0 indicating currently
no edema symptoms and 3 indicating the worst possible
stage, according to the classiﬁcation of the International
Society of Lymphology.18
LEOS study results on other topics than the PBI-L have
been, or will be, published elsewhere.19,20Translation
The PBI-L was translated into English independently by two
professional translators who were English native speakers.
The resulting English versions were each back-translated
into German independently by two professional trans-
lators who were German native speakers. In a conference
with the translators into English and one of the question-
naire developers, each item was discussed using all four
Table 1. Mean, SD, number of missing values, and factor loadings of Patient Needs Questionnaire (PNQ) items (cross-sectional study,
n ¼ 301).
PNQ items (importance
of treatment goals)
n Missing values
(% of 299
patients who
ﬁlled in the PNQ)
“Does not
apply to me”
(% of 299 patients
who ﬁlled in the PNQ)
Meana SDa Factor
loading
factor 1b
Factor
loading,
factor 2b
1. To be free of pain 297 0.7 19.4 3.7 0.7 (.10) .55
2. To experience less
swelling and tension
297 0.7 2.3 3.8 0.5 (.15) .21
3. To have no dry
or sore skin
294 1.7 29.8 3.4 1.0 (.03) .51
4. To experience no skin
discomfort
292 2.4 18.1 3.4 0.9 (.17) .45
5. To cope better with heat 294 1.7 16.4 3.2 1.1 .32 (.14)
6 To be less restricted in
your ability to move around
295 1.4 14.0 3.6 0.8 (.05) .72
7. To be able to stand or sit
for longer periods
295 1.4 17.4 3.5 0.9 (.05) .64
8. To avoid complications 288 3.8 11.4 3.7 0.7 (.10) .69
9. To have no fear that
the disease will
become worse
293 2.1 6.7 3.6 0.9 (.27) .40
10. To be more productive
in everyday life
296 1.0 10.7 3.5 0.9 (.09) .73
11. To be able to exercise
unhindered
294 1.7 13.7 3.3 1.0 .26 (.23)
12. To be less limited in your
choice of clothing
295 1.4 15.7 3.3 1.1 .56 (.07)
13. To receive optimal hosiery
(e.g., color, ﬁt, prescription
quantity)
295 1.4 8.4 3.7 0.7 .24 (.02)
14. To gain more self-assurance
and self-esteem
294 1.7 23.4 3.0 1.3 .77 (.03)
15. To feel more attractive 294 1.7 17.4 3.1 1.2 .84 (.16)
16. To be able to better accept
the condition
294 1.7 16.4 3.0 1.2 .76 (.04)
17. To improve your emotional
sense of wellbeing
292 2.4 20.1 3.0 1.3 .67 (.09)
18. To be able to have more
contact with other people
295 1.4 39.5 2.3 1.5 .57 (.10)
19. To be asked less often
about lymphedema
293 2.1 32.4 2.1 1.5 .63 (.01)
20. To need less time for
treatment
291 2.8 13.0 2.7 1.4 .63 (.04)
21. To have fewer out-of-pocket
treatment expenses
293 2.1 12.7 2.9 1.3 .52 (.02)
22. To ﬁnd a clear diagnosis
and therapy
295 1.4 11.0 3.6 1.0 .43 (.09)
23. To get prescriptions for
treatments more easily
294 1.7 14.0 3.2 1.3 .34 (.13)
a Scale: 0 ¼ “not at all” to 4 ¼ “very”; “does not apply to me” was also coded as 0 for computation of mean and SD.
b Factor loadings in brackets indicate that the item was not assigned the respective subscale.
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the original version; a consensus on the ﬁnal translation
was reached.Longitudinal study
The English PBI-L was implemented in a randomized
clinical trial on patients in the UK and USA suffering from
primary or secondary lymphedema located in arms orlegs. Both groups were subdivided into four groups
receiving different sorts of compression therapy and
additional manual lymphatic drainage and skin care. The
English versions of PBI-L, FLQA-LK (on edema-speciﬁc
HRQoL), and EQ-5D-3L (on generic HRQoL) were
assessed at treatment onset and 19 days later. The clinical
results of the study21 were not an objective of this
investigation.
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The terminology used in this article to describe validation
procedures is in conformity with the COSMIN checklist for
studies evaluating measurement properties of health-
related patient-reported outcomes (www.cosmin.nl).22
The following analyses were performed to evaluate the
PBI-L in the cross-sectional study.
To determine subscales of the PBI-L (and thereby struc-
tural validity) an explorative principal axes factor analysis
with oblique rotation on the needs items (PNQ) was per-
formed. For this analysis, the response “does not apply to
me” was coded as 0. Thereby, it was put on a level with the
response “not at all” important because both answers imply
that the respective goal was not relevant for the patient.
Only factors with an eigenvalue of 1 or higher (i.e., those
that explained more than the variance of a single item)
were extracted. Afterwards, all items were assigned to the
factor they loaded highest on, thereby grouping the items
to subscales. The respective subscale values for each patient
were computed by applying the weighting algorithm
described above, that is, weighting the beneﬁts within the
respective domain by their importance to the individual
patient.
To determine internal consistency within the different
subscales, Cronbach’s alpha was computed for the respec-
tive PNQ items of each subscale. The response “does not
apply to me” was, again, coded as 0.
The strict focus of item development on the results of the
open item collection and the participation of edema pa-
tients in the expert panel should ensure that the items were
relevant for the population of edema patients (content
validity). As an indicator of irrelevant item content, the
percentage of patients choosing “does not apply to me” in
the PNQ was computed for all items. Additionally, the
amount of missing values was computed, because many
missing observations were assumed to indicate that an item
was incomprehensible or irrelevant for the patients.
To test for construct validity, we made hypotheses about
the associations of PBI-L global and subscale scores with
different convergent criteria such as HRQoL and current
health state in advance. These hypotheses are described in
detail in the “Results” section.
To test for responsiveness, we hypothesized associations
of the PBI-L with change in HRQoL in the longitudinal study
in advance (see “Results” section) and tested them by
correlating post-treatment values of PBI-L and HRQoL
measures, controlling for baseline HRQoL values (partial
correlations).RESULTS
Item collection and pilot version
Of the 120 item collection questionnaires distributed to
patients, 65 (54.2%) were ﬁlled in and returned. Of these
patients, 72.3% had leg edema, 15.4% arm edema, and
12.3% both leg and arm edema; 10.8% had primary edema,
30.8% secondary edema, and 40.0% had lipedema orlipolymphedema (18.5% missing). Based on the impair-
ments and treatment goals described by these patients, 23
non-redundant items on patient-relevant treatment goals
could be formulated by the expert panel (Table 1).Patients
Thirty-three centres recruited patients for the cross-
sectional LEOS study, including 15 physiotherapists, seven
general practitioners, four hospitals, three medical supply
stores, three lymphologists, and one dermatologist. 348
patients were interviewed, of whom 301 also returned the
patient questionnaire; the analyses reported in this article
are based on these 301 patients.
Of these 301 patients, 91.7% (n¼ 276) were women. Mean
age was 57.4  14.3 years (range, 24e89 years). In 19.6%
(n ¼ 59), the edema was located in the arm(s), in 63.5%
(n ¼ 191) in the leg(s), and 16.9% (n ¼ 51) had combined leg
and arm edema. 21.9% (n ¼ 66) had primary lymphedema,
43.5% (n¼ 131) secondary lymphedema, and 1.0% (n¼ 3) had
both; 33.6% (n ¼ 101) had lipedema or lipolymphedema.
Eighty-two patients were included in the longitudinal
study; 93.9% (n ¼ 77) were women. 48.8% (n ¼ 40) had leg
edema and 51.2% (n ¼ 42) had arm edema. Average age
was 60.2  13.9 years (range, 24e87 years). The four
treatment groups comprised between 18 and 22 patients.Structural validity
In the explorative factor analysis, 265 patients without
missing values in the PNQ were included. Six factors with an
eigenvalue >1 were found, explaining 61.6% of overall
variance. A subsequent factor analysis was conducted
restricting the number of factors to two for two reasons: (1)
the scree plot suggested that only two factors represented
more than measurement error because a bend was visible
between factor 2 and 3; (2) after rotation, only two of the
factors remained with an eigenvalue >1. These two factors
explained 35.4% of overall variance.
The ﬁrst subscale was interpreted as “normal everyday-
life and psychological wellbeing” and comprised 14 items
(Table 1). The second subscale comprised the remaining
nine items and was interpreted as “physical wellbeing and
capability”.Distribution of PBI-L scores
The treatment goal rated most important by the patients in
the cross-sectional study was “to experience less swelling
and tension” (mean: 3.8 on the scale of 0e4; Table 1). The
goal rated least important was “to be asked less often about
lymphedema” (mean: 2.1). Less swelling and tension was
also the goal rated as best achieved by the patients for
whom it was applicable (mean beneﬁt of 2.8; Table 2). The
lowest treatment beneﬁt was achieved regarding the goals
“less time for treatment” and “fewer out-of-pocket treat-
ment expenses”, with an average value of 1.0 each.
One patient (0.4%, in n ¼ 285) had the lowest possible
PBI-L score of 0.0; 15 patients (5.3%) had the highest
Table 2. Mean, SD, and number of missing values in Patient Beneﬁt Questionnaire (PBQ) items (cross-sectional study, n ¼ 301).
PBQ items (achievement
of treatment goals)
n Missing values
(% of 289 patients
who ﬁlled in the PBQ)
Meana (of patients
who did not tick
“does not apply”)
SDa (of patients who
did not tick “does
not apply”)
1. To be free of pain 285 1.4 2.5 1.1
2. To experience less swelling
and tension
287 0.7 2.8 1.1
3. To have no dry or sore skin 284 1.7 2.1 1.4
4. To experience no skin discomfort 283 2.1 2.3 1.2
5. To cope better with heat 285 1.4 1.6 1.4
6. To be less restricted in my
ability to move around
285 1.4 2.4 1.3
7. To be able to stand or sit for
longer periods
285 1.4 2.2 1.3
8. To avoid complications 283 2.1 2.7 1.3
9. To have no fear that
the disease will become worse
284 1.7 2.2 1.4
10. To be more productive in
everyday life
288 0.3 2.1 1.3
11. To be able to exercise
unhindered
287 0.7 1.9 1.4
12. To be less limited in my
choice of clothing
286 1.0 1.5 1.5
13. To receive optimal hosiery
(e.g., color, ﬁt, prescription
quantity)
284 1.7 2.6 1.4
14. To gain more self-assurance
and self-esteem
284 1.7 1.9 1.4
15. To feel more attractive 286 1.0 1.7 1.4
16. To be able to better accept
the condition
283 2.1 2.2 1.4
17. To improve your emotional sense
of wellbeing
286 1.0 1.9 1.4
18. To be able to have more contact
with other people
287 0.7 1.3 1.3
19. To be asked less often about
lymphedema
285 1.4 1.2 1.4
20. To need less time for treatment 283 2.1 1.0 1.3
21. To have fewer out-of-pocket
treatment expenses
284 1.7 1.0 1.5
22. To ﬁnd a clear diagnosis
and therapy
285 1.4 2.4 1.5
23. To get prescriptions for
treatments more easily
287 0.7 2.1 1.6
a Scale: 0 ¼ “not at all” to 4 ¼ “very”; “does not apply to me” was not coded as 0 here.
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2.2  1.0 (median 2.1).
The mean score of subscale 1 (normal everyday-life and
psychological wellbeing) was 1.8  1.1 (median 1.6). Two
patients (0.7%, n ¼ 281) had the lowest possible score; ten
patients (3.6%) had the highest possible score. The mean
score of subscale two (physical wellbeing and capability)
was 2.2  1.0 (median 2.2), indicating a higher treatment
beneﬁt in this area as compared with subscale one. Two
patients (0.7%, n ¼ 284) had the lowest possible score; 17
patients (6.0%) had the highest possible score.
Internal consistency
Cronbach’s alpha for the PNQ items of subscale 1 was 0.87
(n ¼ 281). Corrected itemescale correlations rangedbetween 0.24 (“to receive optimal hosiery”) and 0.71 (“to
gain more self-assurance and self-esteem”).
Cronbach’s alpha for the PNQ items of subscale two was
0.82 (n ¼ 276). Corrected item-scale-correlations ranged
between 0.29 (“to experience less swelling and tension”)
and 0.66 (“be more productive in everyday life”).
Content validity
The percentage of patients choosing “does not apply to me”
in the PNQ ranged between 2.3% for the goal “less swelling
and tension” and 39.5% for “more contact with other
people” (Table 2). Thus, each item was applicable to more
than 60% of the patients.
All 301 patients who returned the patient questionnaire
ﬁlled in the PBI, at least partially. 299 (99.3%) ﬁlled in the PNQ
Table 3. Hypothesis testing: correlation of Patient Beneﬁt Indexelymphedema and lipedema (PBI-L) global score and subscales with
convergent criteria.
Convergent criterion PBI-L global score PBI-L subscale 1 (normal
everyday-life and psychological
wellbeing)
PBI-L subscale 2 (physical wellbeing
and capability)
n r p n r p n r p
Cross-sectional study
Generic HRQoL:
EQ-5D-3L
283 .21 <.001 279 .15 .012 282 .15 .013
Generic HRQoL:
global assessment
279 .29 <.001 275 .23 <.001 278 .18 .002
Disease-speciﬁc HRQoL:
FLQA-LKa
279 .31 <.001 275 .27 <.001 278 .19 .002
Generic health state:
EQ-5D-VAS
282 .25 <.001 278 .22 <.001 281 .18 .002
Disease-speciﬁc health
state: global assessment
279 .50 <.001 275 .44 <.001 278 .36 <.001
Patient assessment of
quality of care
283 .52 <.001 279 .45 <.001 282 .45 <.001
Patient satisfaction
with care
283 .47 <.001 279 .42 <.001 282 .37 <.001
Clinical severity:
edema stageb
282 .14 .017 278 .13 .028 281 .15 .013
Longitudinal study
Generic HRQoL: EQ-5D-3L
after treatment, controlled
for baseline values
62 .09 .478 61 .06 .629 61 .01 .923
Disease-speciﬁc HRQoL:
FLQA-LK after treatment,
controlled for baseline values
74 .34 .003 73 .34 .050 73 .34 .004
Note. HRQoL ¼ health-related quality of life; FLQA-LK ¼ short version of Freiburg Life Quality Assessment in Lymphedema (FLQA-L);
VAS ¼ visual analogue scale.
a In the FLQA-LK, lower values represent better quality of life.
b Correlations with edema stage were analyzed with non-parametric Spearman correlations. All other correlations were Pearson
correlations.
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did not ﬁll in the PBQ, four stated that they currently received
no treatment at all (free text in the PBQ questionnaire), seven
gave no information on current treatment, and one wrote
that he currently received lymph therapy.
Among those patients who ﬁlled in the PNQ, between
0.7% and 3.8% had missing values, depending on the item
(average: 1.8%; Table 1). The PNQ items with the highest
number of missing values were “to avoid complications”
(3.8%) and “to need less time for treatment” (2.8%).
In the PBQ, there were between 0.3% and 2.1% missing
values in those 289 patients who completed the question-
naire (average: 1.4%; Table 2). The PBQ items with the
highest rate of missing values were “to experience less
swelling and tension” (2.8%) and, as in the PNQ, “to avoid
complications” (2.7%).
Construct validity
We had hypothesized a positive correlation of PBI-L with
HRQoL, with the highest correlation regarding the disease-
speciﬁc instrument FLQA-LK. PBI-L global score and sub-
scales correlated with all three measures of HRQoL
(Table 3). The effect was of low-to-medium size (absolute
r ¼ .15e.31). Correlations with the disease-speciﬁcinstrument FLQA-LK were higher than with the generic in-
struments, but only slightly so.
We had hypothesized a positive correlation of PBI-L with
patient assessment of current health state (EQ-VAS on
health state in general; global assessment of health state
regarding the edema) with a higher correlation with the
edema-speciﬁc measurement. As predicted, the correla-
tions with the edema-speciﬁc measure were markedly
higher (r ¼ .36e.50) than with the generic measure
(r ¼ .18e.25).
A positive correlation of PBI-L with patients’ assessment
of quality of care and satisfaction with care was found, as
hypothesized (medium-to-high effect sizes of r ¼ .37e.52).
The hypothesis that the correlation with satisfaction would
be higher than with quality of care could not be conﬁrmed.
The hypothesized negative correlation of PBI-L global
score and subscales with edema stage was also found,
implying that patients with a lower clinical severity rated
treatment beneﬁt as higher. However, correlations were low
(r ¼ .13 to .15).
Responsiveness
We had hypothesized that PBI-L global score and subscales
correlate positively with change in HRQoL, and that the
106 C. Blome et al.correlation with the disease-speciﬁc instrument FLQA-LK
would be higher. A positive correlation was found with
change in disease-speciﬁc HRQoL (FLQA-LK). The effect was
of medium size (r ¼ .34) and signiﬁcant. The correlations
with generic HRQoL (EQ-5D-3L) were very low (r ¼ .01
to .09) and not signiﬁcant.DISCUSSION
The aim of this study was to develop and validate the PBI-L,
a questionnaire for the assessment of patient-relevant
beneﬁt in lymphedema and lipedema treatment.
With the PBI-L, patients rate the extent to which their
treatment goals have been achieved. By doing so, they both
rate the improvement since treatment onset and judge
whether the improvement is caused by treatment. In
contrast to HRQoL questionnaires where preepost differ-
ences are usually interpreted as treatment effects, patients
can exclude changes not caused by treatment from their
beneﬁt assessment in the PBI-L. Furthermore, treatment
beneﬁt is assessed retrospectively. In contrast, HRQoL
questionnaires are usually used prospectively, which means
that beneﬁt is evaluated by computing preepost HRQoL
differences. The PBI-L also comprises a pre-treatment
assessment with the PNQ, but this only concerns goal
importance; the beneﬁt assessment with the PBQ is con-
ducted after treatment only. This retrospective assessment
prevents response shift effects. However, it involves the risk
of recall bias if patients do not correctly recall the extent of
their impairment before therapy and therefore make a
biased beneﬁt assessment. The question of whether a recall
bias occurs in the PBI is currently being investigated in a
longitudinal study.
We wanted to be certain that the PBI-L covers all treat-
ment goals that are relevant to edema patients. Therefore,
we conducted an open item collection regarding goals and
impairments in patients with different types of edema
(primary, secondary, lip- and lymphedema, localized at arms
or legs), and we involved patients in the discussion of, and
decision on, the ﬁnal items.
In the quantitative analysis of the cross-sectional and the
longitudinal study, well-interpretable PBI-L subscales
providing more detailed information on patient beneﬁt in
addition to the PBI global score were found. Floor and
ceiling effects were small, all items were applicable to the
majority of the patients, and the amount of missing values
was low.
To examine construct validity in this study, hypotheses
were deﬁned a priori, which could largely be conﬁrmed.
Both PBI-L global score and subscales correlated with the
convergent criteria, and the association was higher
regarding disease-speciﬁc measures of HRQoL and current
health state as compared to measures of non-edema-
speciﬁc aspects of health. A high correlation was found
with patients’ assessment of quality of care and satisfaction
with care. This is plausible because both measures repre-
sent retrospective assessments just as the PBI-L does, as
opposed to the HRQoL and health state measures, whichonly assess the current state. In contrast to our assumption
that satisfaction with care was more similar to the construct
of treatment beneﬁt, the association of patient assessment
of quality of care with PBI-L was slightly higher. The low
association of treatment beneﬁt and edema stage might be
explained by the fact that disease severity is inﬂuenced by
many factors beyond quality of treatment, for example by
disease duration.
Good responsiveness was found regarding change in
disease-speciﬁc HRQoL, which correlated markedly with
treatment beneﬁt. However, we could not conﬁrm the hy-
pothesized association with change in generic HRQoL. A
possible explanation might be that the very speciﬁc beneﬁt
of edema treatment is difﬁcult to display with a generic
instrument like the EQ-5D.
With the available data, reliability of the PBI-L could only
be assessed with regard to internal consistency. Further
longitudinal studies will investigate retest reliability.
We conclude that the PBI-L is an internally consistent,
valid, and responsive instrument for the assessment of
patient-relevant beneﬁt of edema treatment suitable for
use in clinical studies and quality of care studies or in
clinical routine.FUNDING
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